Back to top

Image: Bigstock

Horizon Pharma plc

Read MoreHide Full Article

Horizon Pharma’s orphan and rheumatology business units witnessed strong growth. We expect Krystexxa, Ravicti and Actimmune to drive further growth. The acquisition of teprotumumab has further diversified the company’s portfolio. However, revenues from primary care business units declined due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. In June 2017, Horizon Pharma sold the marketing rights for Procysbi and Quinsair in Europe, the Middle East and Africa to Chiesi Farmaceutici S.p.A. to focus on higher return businesses. Shares of the company have outperformed the industry so far this year.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Horizon Therapeutics Public Limited Company (HZNP) - free report >>

Published in